Controlling systolic blood pressure is difficult in patients with diabetic kidney disease exhibiting moderate-to-severe reductions in renal function

被引:13
作者
Sælen, MG
Prosch, LK
Gudmundsdottir, H
Dyrbekk, D
Hunderi, OH
Arnesen, E
Paulsen, D
Skjonsberg, H
Os, I [1 ]
机构
[1] Ullevaal Univ Hosp, Dept Nephrol, N-0407 Oslo, Norway
[2] Univ Oslo, Dept Pharmacotherapeut, Oslo, Norway
[3] Vestfold HF, Tensberg, Norway
[4] Ostfold HF, Fredrikstad, Norway
[5] Innlandet HF Elverum, Elverum, Norway
[6] Innlandet HF Lillehammer, Lillehammer, Norway
[7] Akershus Univ Hosp, Nordbyhagen, Norway
关键词
antihypertensive drugs; blood pressure control; chronic renal failure; diabetic kidney disease;
D O I
10.1080/08037050510008959
中图分类号
R6 [外科学];
学科分类号
1002 ; 100210 ;
摘要
This study compared the use of antihypertensive treatment and blood pressure ( BP) controls between patients with diabetic kidney disease (DK+) and patients with non-diabetic kidney disease (DK-) exhibiting moderate-to-severe chronic renal failure who did not need renal replacement therapy. A cross-sectional survey included all renal patients with s-creatinine at >= 200 mu mol/l attending regular control sessions at six renal units in Norway. Of the 351 patients included, 73 (20.8%) were DK+. The proportion reaching a BP goal of <130/80 mmHg was similar in DK+ and DK- (14.1% vs 13.6%, p=0.92), while 38% and 39% achieved a BP of <140/90 mmHg, respectively. The systolic BP goal was more difficult to achieve than the diastolic BP goal in DK+ patients (35% vs 15%) despite a mean of three different types of drugs being used. Loop diuretics and beta-adrenergic-receptor antagonists were the most frequently prescribed drugs, and the use of angiotensin-converting enzyme inhibitors or angiotensin-II-receptor antagonists declined when renal function deteriorated, from 80% to 0% and from 66% to 20% in the DK+ and DK- groups, respectively (p=0.001). Thus, despite the use of multiple antihypertensive drugs, controlling BP-especially the systolic BP-is difficult in high-risk patients with chronic renal failure caused by diabetic kidney disease.
引用
收藏
页码:170 / 176
页数:7
相关论文
共 33 条
[11]   Characteristics of treated hypertension in incident hemodialysis and peritoneal dialysis patients [J].
Griffith, TF ;
Chua, BSY ;
Allen, AS ;
Klassen, PS ;
Reddan, DN ;
Szczech, LA .
AMERICAN JOURNAL OF KIDNEY DISEASES, 2003, 42 (06) :1260-1269
[12]   Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease - A meta-analysis of patient-level data [J].
Jafar, TH ;
Schmid, CH ;
Landa, M ;
Giatras, I ;
Toto, R ;
Remuzzi, G ;
Maschio, G ;
Brenner, BM ;
Kamper, A ;
Zucchelli, P ;
Becker, G ;
Himmelmann, A ;
Bannister, K ;
Landais, P ;
Shahinfar, S ;
de Jong, PE ;
de Zeeuw, D ;
Lau, J ;
Levey, AS .
ANNALS OF INTERNAL MEDICINE, 2001, 135 (02) :73-87
[13]   Calcium channel blocker use and mortality among patients with end-stage renal disease [J].
Kestenbaum, B ;
Gillen, DL ;
Sherrard, DJ ;
Seliger, S ;
Ball, A ;
Stehman-Breen, C .
KIDNEY INTERNATIONAL, 2002, 61 (06) :2157-2164
[14]   Beneficial effect of combination therapy with an angiotensin II receptor antagonist and angiotensin-converting enzyme inhibitor on overt proteinuria in a patient with type 1 diabetic nephropathy [J].
Kuriyama, S ;
Tomonari, H ;
Abe, A ;
Imasawa, T ;
Hosoya, T .
NEPHRON, 2000, 86 (04) :529-530
[15]   Achievement and safety of a low blood pressure goal in chronic renal disease - The Modification of Diet in Renal Disease Study Group [J].
Lazarus, JM ;
Bourgoignie, JJ ;
Buckalew, VM ;
Greene, T ;
Levey, AS ;
Milas, NC ;
Paranandi, L ;
Peterson, JC ;
Porush, JG ;
Rauch, S ;
Soucie, JM ;
Stollar, C .
HYPERTENSION, 1997, 29 (02) :641-650
[16]   THE EFFECT OF ANGIOTENSIN-CONVERTING ENZYME-INHIBITION ON DIABETIC NEPHROPATHY [J].
LEWIS, EJ ;
HUNSICKER, LG ;
BAIN, RP ;
ROHDE, RD .
NEW ENGLAND JOURNAL OF MEDICINE, 1993, 329 (20) :1456-1462
[17]   2003 European society of hypertension -: European Society of Cardiology guidelines for the management of arterial hypertension [J].
Mancia, G ;
Rosei, EA ;
Cifkova, R ;
DeBacker, G ;
Erdine, S ;
Fagard, R ;
Farsang, C ;
Heagerty, AM ;
Kawecka-Jaszcs, K ;
Kiowski, W ;
Kjeldsen, S ;
Lüscher, T ;
McInnes, G ;
Mallion, JM ;
Brien, EO ;
Poulter, NR ;
Priori, SG ;
Rahn, KH ;
Rodicio, JL ;
Ruilope, LM ;
Safar, M ;
Staessen, JA ;
van Zwieten, P ;
Waeber, B ;
Williams, B ;
Zanchetti, A ;
Zannad, F .
JOURNAL OF HYPERTENSION, 2003, 21 (06) :1011-1053
[18]   Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency [J].
Maschio, G ;
Alberti, D ;
Janin, G ;
Locatelli, F ;
Mann, JFE ;
Motolese, M ;
Ponticelli, C ;
Ritz, E ;
Zucchelli, P ;
Marai, P ;
Marcelli, D ;
Tentori, F ;
Andriani, M ;
Drago, G ;
Meneghel, G ;
Oldrizzi, L ;
Rugiu, C ;
Salvadeo, A ;
Villa, G ;
Picardi, L ;
Borghi, M ;
Moriggi, M ;
Vendramin, G ;
Fusaroli, M ;
Esposti, ED ;
Fabbri, A ;
Koch, KM ;
Frey, U ;
Schaeffer, J ;
Mann, J ;
Schweitzer, C ;
Zuccala, A ;
Gaggi, R ;
Stahl, R ;
Blaser, C ;
Rivolta, E ;
Buccianti, G ;
Gastaldi, L ;
Baratelli, M ;
Ducret, F ;
Pointet, P ;
Sterzel, R ;
Oberdorf, E ;
Pedrini, L ;
Faranna, P ;
Cairo, G ;
Ferrari, L ;
Albertazzi, A ;
Cappelli, P ;
Cantu, P .
NEW ENGLAND JOURNAL OF MEDICINE, 1996, 334 (15) :939-945
[19]   Angiotensin-converting enzyme inhibitors and kidney protection:: The AIPRI trial [J].
Maschio, G ;
Alberti, D ;
Locatelli, F ;
Mann, JFE ;
Motolese, M ;
Ponticelli, C ;
Ritz, E ;
Janin, G ;
Zucchelli, P ;
Marai, P ;
Marcelli, D ;
Tentori, F ;
Andriani, M ;
Drago, G ;
Meneghel, G ;
Oldrizzi, L ;
Rugiu, C ;
Salvadeo, A ;
Villa, G ;
Picardi, L ;
Borghi, M ;
Moriggi, M ;
Vendramin, G ;
Fusaroli, M ;
Esposti, ED ;
Fabbri, A ;
Zucchelli, P ;
Zuccali, A ;
Gaggi, R ;
Ponticelli, C ;
Rivolta, E ;
Buccianti, G ;
Gastaldi, L ;
Baratelli, M ;
Pedrini, L ;
Faranna, P ;
Cairo, G ;
Ferrari, L ;
Albertazzi, A ;
Cappelli, P ;
Canti, P ;
Limido, A ;
Mioni, G ;
Montanaro, D ;
Sasdelli, M ;
Imperiali, P ;
Cagnoli, L ;
Rigotti, A ;
Grassi, C ;
Orazi, E .
JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 1999, 33 :S16-S20
[20]   Changes of serum albumin and C-reactive protein are related to changes of interleukin-6 release by peripheral blood mononuclear cells in hemodialysis patients treated with different membranes [J].
Memoli, B ;
Minutolo, R ;
Bisesti, V ;
Postiglione, L ;
Conti, A ;
Marzano, L ;
Capuano, A ;
Andreucci, M ;
Balletta, MM ;
Guida, B ;
Tetta, C .
AMERICAN JOURNAL OF KIDNEY DISEASES, 2002, 39 (02) :266-273